Obesity and the Risk of Thyroid Cancer: A Literature Review
DOI:
https://doi.org/10.12775/QS.2024.19.54187Keywords
thyroid carcinoma, obesity, overweight, risk factorsAbstract
Introduction and aim of the study: Thyroid cancer is considered the most common endocrine malignant worldwide in recent years. Also, obesity has become a true pandemic. The correlation between the increase in cases of not only obesity but also thyroid cancer could not be explained solely by earlier and more meticulous cancer diagnoses. This study aims to review the literature on the relationship between obesity and the risk of thyroid cancer.
Materials and Methods: The authors conducted a comprehensive review of the literature available in PubMed and Medline databases focusing on the terms "thyroid cancer" and "obesity".
Results: Obesity is associated with a state of chronic inflammation and nonspecific activation of the immune system, leading to the production of cytokines and adipokines. These elements, through complex mechanisms, directly and indirectly promote carcinogenesis. Despite the association of excessive body weight with malignant tumor development, oncological treatment cannot rely solely on lifestyle changes and should be conducted precisely as it is for individuals with normal body weight. Another popular research topic in recent years has been circadian rhythm disorders. These disorders are confirmed to be a pro-carcinogenic factor but are also considered as an element that could accelerate diagnosis.
Conclusions: Understanding the relationship between obesity and thyroid cancer, primarily molecular mechanisms is essential for developing effective preventive and therapeutic strategies to reduce the risk of thyroid cancer in obese patients.
References
C. D. Seib and J. A. Sosa, “Evolving Understanding of the Epidemiology of Thyroid Cancer,” Endocrinol Metab Clin North Am, vol. 48, no. 1, pp. 23–35, Mar. 2019, doi: 10.1016/j.ecl.2018.10.002.
Jassema J and Kordek R, Onkologia, Via Medica. 2019.
A. Miranda-Filho et al., “Thyroid cancer incidence trends by histology in 25 countries: a population-based study,” Lancet Diabetes Endocrinol, vol. 9, no. 4, pp. 225–234, Apr. 2021, doi: 10.1016/S2213-8587(21)00027-9.
E. Pasqual, K. O’Brien, S. Rinaldi, D. P. Sandler, and C. M. Kitahara, “Obesity, obesity-related metabolic conditions, and risk of thyroid cancer in women: results from a prospective cohort study (Sister Study),” The Lancet Regional Health - Americas, vol. 23, p. 100537, Jul. 2023, doi: 10.1016/j.lana.2023.100537.
“World Health Organisation: Obesity and owerweight: fact sheet. www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (March 1, 2024).”
D. Laha, N. Nilubol, and M. Boufraqech, “New Therapies for Advanced Thyroid Cancer,” Front Endocrinol (Lausanne), vol. 11, May 2020, doi: 10.3389/fendo.2020.00082.
Y. Ito, A. Miyauchi, M. Kihara, M. Fukushima, T. Higashiyama, and A. Miya, “Overall Survival of Papillary Thyroid Carcinoma Patients: A Single‐Institution Long‐Term Follow‐Up of 5897 Patients,” World J Surg, vol. 42, no. 3, pp. 615–622, Mar. 2018, doi: 10.1007/s00268-018-4479-z.
“American Cancer Society: Thyroid Cancer https://www.cancer.org/cancer/types/thyroid-cancer.html (January 17, 2024).”
A. Budny et al., “Obesity as a tumour development triggering factor,” Annals of Agricultural and Environmental Medicine, vol. 26, no. 1, pp. 13–23, Mar. 2019, doi: 10.26444/aaem/100664.
T.-V.-T. Tran, C. M. Kitahara, F. de Vathaire, M.-C. Boutron-Ruault, and N. Journy, “Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis,” Endocr Relat Cancer, vol. 27, no. 4, pp. 245–259, Apr. 2020, doi: 10.1530/ERC-19-0417.
C. L. Meinhold et al., “Nonradiation Risk Factors for Thyroid Cancer in the US Radiologic Technologists Study,” Am J Epidemiol, vol. 171, no. 2, pp. 242–252, Jan. 2010, doi: 10.1093/aje/kwp354.
F. Franchini, G. Palatucci, A. Colao, P. Ungaro, P. E. Macchia, and I. C. Nettore, “Obesity and Thyroid Cancer Risk: An Update,” Int J Environ Res Public Health, vol. 19, no. 3, p. 1116, Jan. 2022, doi: 10.3390/ijerph19031116.
T. Kawai, M. V. Autieri, and R. Scalia, “Adipose tissue inflammation and metabolic dysfunction in obesity,” American Journal of Physiology-Cell Physiology, vol. 320, no. 3, pp. C375–C391, Mar. 2021, doi: 10.1152/ajpcell.00379.2020.
J. Zhao, J. Wen, S. Wang, J. Yao, L. Liao, and J. Dong, “Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies,” BMC Cancer, vol. 20, no. 1, p. 788, Dec. 2020, doi: 10.1186/s12885-020-07299-x.
R. Kolb, F. S. Sutterwala, and W. Zhang, “Obesity and cancer: inflammation bridges the two,” Curr Opin Pharmacol, vol. 29, pp. 77–89, Aug. 2016, doi: 10.1016/j.coph.2016.07.005.
V. Lanier et al., “Leptin-induced transphosphorylation of vascular endothelial growth factor receptor increases Notch and stimulates endothelial cell angiogenic transformation,” Int J Biochem Cell Biol, vol. 79, pp. 139–150, Oct. 2016, doi: 10.1016/j.biocel.2016.08.023.
X. Provatopoulou et al., “Interleukins as markers of inflammation in malignant and benign thyroid disease,” Inflammation Research, vol. 63, no. 8, pp. 667–674, Aug. 2014, doi: 10.1007/s00011-014-0739-z.
R. Zheng, G. Chen, X. Li, X. Wei, C. Liu, and M. Derwahl, “Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells.,” Int J Clin Exp Pathol, vol. 12, no. 11, pp. 3992–4001, 2019.
R. Dogan et al., “Oxidative stress values of tumor core, edge, and healthy thyroid tissue in thyroid masses,” European Archives of Oto-Rhino-Laryngology, vol. 278, no. 8, pp. 2953–2960, Aug. 2021, doi: 10.1007/s00405-020-06422-9.
S. Masone et al., “Morbid Obesity and Thyroid Cancer Rate. A Review of Literature,” J Clin Med, vol. 10, no. 9, p. 1894, Apr. 2021, doi: 10.3390/jcm10091894.
L. Marseglia et al., “Oxidative Stress in Obesity: A Critical Component in Human Diseases,” Int J Mol Sci, vol. 16, no. 1, pp. 378–400, Dec. 2014, doi: 10.3390/ijms16010378.
D. Yin et al., “The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: A systematic review and meta-analysis,” International Journal of Surgery, vol. 57, pp. 66–75, Sep. 2018, doi: 10.1016/j.ijsu.2018.07.013.
J. N. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, and H. Niepomniszcze, “Increased Prevalence of Insulin Resistance in Patients With Differentiated Thyroid Carcinoma,” Metab Syndr Relat Disord, vol. 7, no. 4, pp. 375–380, Aug. 2009, doi: 10.1089/met.2008.0062.
S. Nam et al., “Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone,” Int J Obes, vol. 21, no. 5, pp. 355–359, May 1997, doi: 10.1038/sj.ijo.0800412.
A. Belfiore, G. Pandini, V. Vella, S. Squatrito, and R. Vigneri, “Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer,” Biochimie, vol. 81, no. 4, pp. 403–407, Apr. 1999, doi: 10.1016/S0300-9084(99)80088-1.
S. J. Moschos and C. S. Mantzoros, “The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications,” Oncology, vol. 63, no. 4, pp. 317–332, 2002, doi: 10.1159/000066230.
T. Modric, K. Rajkumar, and L. Murphy, “Thyroid gland function and growth in IGF binding protein-1 transgenic mice,” Eur J Endocrinol, pp. 149–159, Aug. 1999, doi: 10.1530/eje.0.1410149.
T. Pappa and M. Alevizaki, “Obesity and Thyroid Cancer: A Clinical Update,” Thyroid, vol. 24, no. 2, pp. 190–199, Feb. 2014, doi: 10.1089/thy.2013.0232.
J. Liu, T. Xu, L. Ma, and W. Chang, “Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer,” Front Oncol, vol. 11, Apr. 2021, doi: 10.3389/fonc.2021.593479.
G. A. Rubio, P. Catanuto, M. K. Glassberg, J. I. Lew, and S. J. Elliot, “Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause,” Surgery, vol. 163, no. 1, pp. 143–149, Jan. 2018, doi: 10.1016/j.surg.2017.04.031.
K. B. Smith and M. S. Smith, “Obesity Statistics,” Prim Care, vol. 43, no. 1, pp. 121–135, Mar. 2016, doi: 10.1016/J.POP.2015.10.001.
K. I. Avgerinos, N. Spyrou, C. S. Mantzoros, and M. Dalamaga, “Obesity and cancer risk: Emerging biological mechanisms and perspectives,” Metabolism, vol. 92, pp. 121–135, Mar. 2019, doi: 10.1016/J.METABOL.2018.11.001.
A. Budny et al., “Obesity as a tumour development triggering factor,” Ann Agric Environ Med, vol. 26, no. 1, pp. 13–23, 2019, doi: 10.26444/AAEM/100664.
X. N. Ma, C. X. Ma, L. J. Hou, and S. B. Fu, “The association of obesity with thyroid carcinoma risk,” Cancer Med, vol. 11, no. 4, pp. 1136–1144, Feb. 2022, doi: 10.1002/CAM4.4498.
A. Matrone, F. Ferrari, F. Santini, and R. Elisei, “Obesity as a risk factor for thyroid cancer,” Curr Opin Endocrinol Diabetes Obes, vol. 27, no. 5, pp. 358–363, Oct. 2020, doi: 10.1097/MED.0000000000000556.
T. Bogović Crnčić, “Risk Factors for Thyroid Cancer: What Do We Know So Far?,” Acta Clin Croat, 2020, doi: 10.20471/acc.2020.59.s1.08.
A. Harikrishna et al., “The impact of obesity and insulin resistance on thyroid cancer: A systematic review,” Maturitas, vol. 125, pp. 45–49, Jul. 2019, doi: 10.1016/J.MATURITAS.2019.03.022.
A. Matrone, F. Ferrari, F. Santini, and R. Elisei, “Obesity as a risk factor for thyroid cancer,” Curr Opin Endocrinol Diabetes Obes, vol. 27, no. 5, pp. 358–363, Oct. 2020, doi: 10.1097/MED.0000000000000556.
S. Zhao et al., “Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: A retrospective case-control study,” Medicine (United States), vol. 98, no. 50, 2019, doi: 10.1097/MD.0000000000018213.
C. M. Kitahara et al., “Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies,” Thyroid, vol. 26, no. 2, pp. 306–318, Feb. 2016, doi: 10.1089/THY.2015.0319.
A. Matrone et al., “Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer,” J Clin Endocrinol Metab, vol. 105, no. 4, pp. e1124–e1134, Apr. 2020, doi: 10.1210/clinem/dgz312.
C. Savvidis et al., “Circadian rhythm disruption and endocrine-related tumors,” World J Clin Oncol, vol. 15, no. 7, pp. 818–834, Jul. 2024, doi: 10.5306/wjco.v15.i7.818.
R. Malaguarnera et al., “Thyroid Cancer and Circadian Clock Disruption,” Cancers (Basel), vol. 12, no. 11, pp. 1–26, Nov. 2020, doi: 10.3390/CANCERS12113109.
J. Luo, M. Sands, J. Wactawski-Wende, Y. Song, and K. L. Margolis, “Sleep Disturbance and Incidence of Thyroid Cancer in Postmenopausal Women The Women’s Health Initiative,” Am J Epidemiol, vol. 177, no. 1, pp. 42–49, Jan. 2013, doi: 10.1093/aje/kws193.
D. Zhang, R. R. Jones, P. James, C. M. Kitahara, and Q. Xiao, “Associations between artificial light at night and risk for thyroid cancer: A large US cohort study,” Cancer, vol. 127, no. 9, pp. 1448–1458, May 2021, doi: 10.1002/cncr.33392.
X. Zhu, G. Maier, and S. Panda, “Learning from circadian rhythm to transform cancer prevention, prognosis, and survivorship care,” Trends Cancer, vol. 10, no. 3, pp. 196–207, Mar. 2024, doi: 10.1016/j.trecan.2023.11.002.
K. Ikegami, S. Refetoff, E. Van Cauter, and T. Yoshimura, “Interconnection between circadian clocks and thyroid function,” Nat Rev Endocrinol, vol. 15, no. 10, pp. 590–600, Oct. 2019, doi: 10.1038/s41574-019-0237-z.
E. Maury, K. M. Ramsey, and J. Bass, “Circadian Rhythms and Metabolic Syndrome,” Circ Res, vol. 106, no. 3, pp. 447–462, Feb. 2010, doi: 10.1161/CIRCRESAHA.109.208355.
F. C. Kelleher, A. Rao, and A. Maguire, “Circadian molecular clocks and cancer,” Cancer Lett, vol. 342, no. 1, pp. 9–18, Jan. 2014, doi: 10.1016/j.canlet.2013.09.040.
C. Miro et al., “‘Time’ for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment,” Semin Cancer Biol, vol. 91, pp. 99–109, Jun. 2023, doi: 10.1016/j.semcancer.2023.03.003.
L. Sjöström et al., “Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial,” Lancet Oncol, vol. 10, no. 7, pp. 653–662, Jul. 2009, doi: 10.1016/S1470-2045(09)70159-7.
T. D. Adams et al., “Long‐term cancer outcomes after bariatric surgery,” Obesity, vol. 31, no. 9, pp. 2386–2397, Sep. 2023, doi: 10.1002/oby.23812.
R. B. Wilson, D. Lathigara, and D. Kaushal, “Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk,” Int J Mol Sci, vol. 24, no. 7, p. 6192, Mar. 2023, doi: 10.3390/ijms24076192.
C. L. Li, G. Dionigi, Y. S. Zhao, N. Liang, and H. Sun, “Influence of body mass index on the clinicopathological features of 13,995 papillary thyroid tumors,” J Endocrinol Invest, vol. 43, no. 9, pp. 1283–1299, Sep. 2020, doi: 10.1007/s40618-020-01216-6.
M. Kim et al., “Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study,” Endocrine, vol. 82, no. 1, pp. 134–142, Oct. 2023, doi: 10.1007/S12020-023-03416-5/METRICS.
D. Gąsior-Perczak et al., “The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer,” PLoS One, vol. 13, no. 10, p. e0204668, Oct. 2018, doi: 10.1371/journal.pone.0204668.
A. Matrone, A. Basolo, F. Santini, and R. Elisei, “Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management?,” Expert Rev Endocrinol Metab, vol. 17, no. 6, pp. 475–484, Nov. 2022, doi: 10.1080/17446651.2022.2131529.
S. Simati, A. Kokkinos, M. Dalamaga, and G. Argyrakopoulou, “Obesity Paradox: Fact or Fiction?,” Curr Obes Rep, vol. 12, no. 2, pp. 75–85, Feb. 2023, doi: 10.1007/s13679-023-00497-1.
Y. Park, L. L. Peterson, and G. A. Colditz, “The Plausibility of Obesity Paradox in Cancer—Point,” Cancer Res, vol. 78, no. 8, pp. 1898–1903, Apr. 2018, doi: 10.1158/0008-5472.CAN-17-3043.
I. Trestini, L. Carbognin, C. Bonaiuto, G. Tortora, and E. Bria, “The obesity paradox in cancer: clinical insights and perspectives,” Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, vol. 23, no. 2, pp. 185–193, Apr. 2018, doi: 10.1007/s40519-018-0489-y.
K.-N. Kim et al., “Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study,” Sci Rep, vol. 10, no. 1, p. 5000, Mar. 2020, doi: 10.1038/s41598-020-59245-3.
J. Park, H. Park, T. H. Kim, S. W. Kim, H. W. Jang, and J. H. Chung, “Trends in Childhood Thyroid Cancer incidence in Korea and Its Potential Risk Factors,” Front Endocrinol (Lausanne), vol. 12, May 2021, doi: 10.3389/fendo.2021.681148.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Karolina Piątkowska, Aleksandra Jaroń, Agata Wiklińska, Martyna Śliwińska, Katarzyna Wójtowicz, Agata Walczak, Wiktoria Niegowska, Jakub Wirkijowski, Wiktoria Gajek-Flanczewska, Sebastian Flanczewski, Paulina Woźniak, Kajetan Kidacki
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 216
Number of citations: 0
